GAVRETO

This brand name is authorized in Austria, Ecuador, Estonia, France, Croatia, Ireland, Israel, Italy, Lithuania, Poland, Romania, United States

Active ingredients

The drug GAVRETO contains one active pharmaceutical ingredient (API):

1 Pralsetinib UNII 1WPE73O1WV - PRALSETINIB

Pralsetinib is a potent protein kinase inhibitor that selectively targets oncogenic RET fusions (KIF5BRET and CCDC6-RET). In non-small cell lung cancer (NSCLC), RET fusions are one of the main oncogenic drivers. Read about Pralsetinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
GAVRETO Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR
GAVRETO Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX23		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 6644-MEE-1021
Country: EE	Ravimiamet	Identifier(s): 1867765, 1867776, 1867787
Country: FR	Base de données publique des médicaments	Identifier(s): 67194402
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9015, 9016, 9017
Country: IT	Agenzia del Farmaco	Identifier(s): 049771013, 049771025, 049771037
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093820, 1093821, 1093822
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100460685
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68296001, W68296002
Country: US	FDA, National Drug Code	Identifier(s): 72064-210